Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy

Nephrolithiasis Clinical Trial

Official title:

Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02966236
• Other study ID #: TXA
• Status: Recruiting
• Phase: Phase 4
• Start date: June 2016
• Est. completion date: June 2019

Study information

• Verified date: May 2018
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a double blinded randomized controlled trial evaluating the impact of tranexamic acid use on the transfusion rate in patients with complex kidney stones undergoing percutaneous nephrolithotomy.

Description:

Introduction: Kidney stone is a high incidence and prevalent disease affecting people around the world. Nearly 1 in 11 individuals in the United States will be affected at some point in their lives. Furthermore, stones are likely to recur with at least 50% of individuals experiencing another stone within 10 years of the first occurrence. Moreover, the disease mainly affects the economically active segment of the population with special social and economic implications in health.

Approximately 85% of stones are composed predominantly by calcium compounds and about 7% are attributed to urinary tract infections, named struvite stones, that usually develop as jagged structures called "staghorns" and can grow to be quite large, therefore becoming complex kidney stone. However, in HCFMUSP, as a Brazilian national reference center in urolithiasis treatment, this complex stones represents about 30 percent of all renal lithiasis treated.

This complex stones require individualized and specialized treatment, with percutaneous nephrolithotomy (PCNL) as the standard of care, with advantages of higher stone clearance and cost-effectiveness when compared with other treatment alternatives.

However, PCNL is associated with significant morbidity such as fever, urinary infections, septicemia and bleeding that may require blood transfusion. Of these complications bleeding is the most unpredictable and dreaded, and can lead to significant morbidity, beyond the potential risks of blood transfusions by itself.

In this way antifibrinolytic drugs, such as tranexamic acid, have been shown to reduce blood loss in a variety of surgical procedures, blood transfusion rate, morbidity and mortality related to bleeding.

Objectives: The main outcome measure of our study is to evaluate the impact of tranexamic acid use in blood transfusion rate in patients with complex kidney stones undergoing PCNL (number of patients receiving blood transfusions from surgery until hospital discharge). The secondary outcome is to evaluate blood loss by hemoglobin measure, surgical time, stone free rate and complications. Furthermore, we want to corroborate the drug safety, previously established in the medical literature.

Methods: After protocol approval by the hospital ethics committee, patients undergoing PCNL for complex renal stone (GUYS classification III and IV) and who provided written informed consent, will be eligible for the trial. After the patients' eligibility is confirmed, we will randomly allocate them to the intervention or placebo group by a computer program. Trial participants, care providers, surgeons, the anesthesiology team and data collectors will be blinded to group assignments. Patients will be managed with surgical standardized technique by Endourological HCFMUSP group and controlled care after surgery. Blood transfusion rate, hemoglobin drop and complications will be evaluated at 7, 30, 90 and 180 days after surgery. On postoperative day one, CT scan will be performed to assess stone free rate and complications.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 192
• Est. completion date: June 2019
• Est. primary completion date: June 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Complex kidney stone (staghorn calculi GUYS III and IV)

Exclusion Criteria:

• Coronary artery disease - stent

• Severe chronic renal failure

• Congenital or acquired thrombophilia/thrombosis event

• Known or suspected allergy

Related Conditions & MeSH terms

• Calculi
• Kidney Calculi
• Nephrolithiasis
• Staghorn Calculus

Intervention

Drug:
• Tranexamic Acid

• Placebos

Locations

Country	Name	City	State
Brazil	University of Sao Paulo Medical School	Sao Paulo

Sponsors (2)

Lead Sponsor	Collaborator
University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	blood transfusion rate	postoperative follow up	two years
Secondary	blood loss	postoperative follow up	two years
Secondary	surgical time	postoperative follow up	two years
Secondary	stone free rate	postoperative follow up	two years
Secondary	complications	postoperative follow up	two years